SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

(Amendment No.     )*

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(1)         This Schedule 13G is filed by 5AM Ventures IV, L.P., a Delaware limited partnership (“Ventures IV”), 5AM Co-Investors IV, L.P., a Delaware limited partnership (“Co-Investors IV”), 5AM Partners IV, LLC, a Delaware limited liability company (“Partners IV”), Dr. John D. Diekman (“Diekman”), Andrew J. Schwab (“Schwab”), and Dr. Scott M. Rocklage (“Rocklage” and together with Ventures IV, Co-Investors IV, Partners IV, Diekman and Schwab, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)         Partners IV serves as the sole general partner of Ventures IV.  Diekman, Schwab and Rocklage are managing members of Partners IV and share voting and dispositive power over the shares held by Ventures IV.  The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of July 20, 2018.

(3)         This percentage is calculated based on 23,007,961 shares of Common Stock outstanding as of July 20, 2018 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus (the “Prospectus”) filed with the Securities and Exchange Commission (the “SEC”) on July 18, 2018 pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended.  The number of shares of Common Stock outstanding does not give effect to the underwriters’ option to purchase up to an additional 900,000 shares of Common Stock within 30 days from the date of the Prospectus.

2

(1)         This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)         Partners IV serves as the sole general partner of Co-Investors IV.  Diekman, Schwab and Rocklage are managing members of Partners IV and share voting and dispositive power over the shares held by Co-Investors IV.  The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of July 20, 2018.

(3)         This percentage is calculated based on 23,007,961 shares of Common Stock outstanding as of July 20, 2018 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus (the “Prospectus”) filed with the Securities and Exchange Commission (the “SEC”) on July 18, 2018 pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended.  The number of shares of Common Stock outstanding does not give effect to the underwriters’ option to purchase up to an additional 900,000 shares of Common Stock within 30 days from the date of the Prospectus.

3

(1)         This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)         Includes 3,359,309 shares of Common Stock held by Ventures IV and 139,969 shares of Common Stock held by Co-Investors IV.  Partners IV serves as the sole general partner of Ventures IV and Co-Investors IV.  Diekman, Schwab and Rocklage are managing members of Partners IV and share voting and dispositive power over the shares held by Ventures IV and Co-Investors IV.  The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of July 20, 2018.

(3)         This percentage is calculated based on 23,007,961 shares of Common Stock outstanding as of July 20, 2018 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus (the “Prospectus”) filed with the Securities and Exchange Commission (the “SEC”) on July 18, 2018 pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended.  The number of shares of Common Stock outstanding does not give effect to the underwriters’ option to purchase up to an additional 900,000 shares of Common Stock within 30 days from the date of the Prospectus.

4

(1)         This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)         Includes 3,359,309 shares of Common Stock held by Ventures IV and 139,969 shares of Common Stock held by Co-Investors IV.  Partners IV serves as the sole general partner of Ventures IV and Co-Investors IV.  Diekman, Schwab and Rocklage are managing members of Partners IV and share voting and dispositive power over the shares held by Ventures IV and Co-Investors IV.  The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of July 20, 2018.

(3)         This percentage is calculated based on 23,007,961 shares of Common Stock outstanding as of July 20, 2018 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus (the “Prospectus”) filed with the Securities and Exchange Commission (the “SEC”) on July 18, 2018 pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended.  The number of shares of Common Stock outstanding does not give effect to the underwriters’ option to purchase up to an additional 900,000 shares of Common Stock within 30 days from the date of the Prospectus.

5

(1)         This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)         Includes 3,359,309 shares of Common Stock held by Ventures IV and 139,969 shares of Common Stock held by Co-Investors IV.  Partners IV serves as the sole general partner of Ventures IV and Co-Investors IV.  Diekman, Schwab and Rocklage are managing members of Partners IV and share voting and dispositive power over the shares held by Ventures IV and Co-Investors IV.  The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of July 20, 2018..

(3)         This percentage is calculated based on 23,007,961 shares of Common Stock outstanding as of July 20, 2018 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus (the “Prospectus”) filed with the Securities and Exchange Commission (the “SEC”) on July 18, 2018 pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended.  The number of shares of Common Stock outstanding does not give effect to the underwriters’ option to purchase up to an additional 900,000 shares of Common Stock within 30 days from the date of the Prospectus.

6

(1)         This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)         Includes 3,359,309 shares of Common Stock held by Ventures IV and 139,969 shares of Common Stock held by Co-Investors IV.  Partners IV serves as the sole general partner of Ventures IV and Co-Investors IV.  Diekman, Schwab and Rocklage are managing members of Partners IV and share voting and dispositive power over the shares held by Ventures IV and Co-Investors IV.  The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of July 20, 2018.

(3)         This percentage is calculated based on 23,007,961 shares of Common Stock outstanding as of July 20, 2018 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus (the “Prospectus”) filed with the Securities and Exchange Commission (the “SEC”) on July 18, 2018 pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended.  The number of shares of Common Stock outstanding does not give effect to the underwriters’ option to purchase up to an additional 900,000 shares of Common Stock within 30 days from the date of the Prospectus.

7

Introductory Note: This Statement on Schedule 13G (this “Statement”) is filed on behalf of the Reporting Persons, in respect of shares of Common Stock, par value $0.001 per share (“Common Stock”), of Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”).

8

(1)         Includes 3,359,309 shares of Common Stock held by Ventures IV.

(2)         Includes 139,969 shares of Common Stock held by Co-Investors IV.

(3)         Partners IV serves as the sole general partner of Ventures IV and Co-Investors IV.  Diekman, Schwab and Rocklage are managing members of Partners IV and share voting and dispositive power over the shares held by Ventures IV and Co-Investors IV.

(4)         This percentage is calculated based on 23,007,961 shares of Common Stock outstanding as of July 20, 2018 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus (the “Prospectus”) filed with the Securities and Exchange Commission (the “SEC”) on July 18, 2018 pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended.  The number of shares of Common Stock outstanding does not give effect to the underwriters’ option to purchase up to an additional 900,000 shares of Common Stock within 30 days from the date of the Prospectus

9

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: July 30, 2018

10

Exhibit(s):

A - Joint Filing Statement

11

EXHIBIT A

JOINT FILING STATEMENT

We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Crinetics Pharmaceuticals, Inc. is filed on behalf of each of us.

Dated: July 30, 2018